BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 30504300)

  • 1. Managing myelofibrosis (MF) that "blasts" through: advancements in the treatment of relapsed/refractory and blast-phase MF.
    Scherber RM; Mesa RA
    Hematology Am Soc Hematol Educ Program; 2018 Nov; 2018(1):118-126. PubMed ID: 30504300
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of challenging myelofibrosis after JAK inhibitor failure and/or progression.
    Scherber RM; Mesa RA
    Blood Rev; 2020 Jul; 42():100716. PubMed ID: 32593470
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data.
    Palandri F; Breccia M; Tiribelli M; Bonifacio M; Benevolo G; Iurlo A; Elli EM; Binotto G; Tieghi A; Polverelli N; Martino B; Abruzzese E; Bergamaschi M; Heidel FH; Cavazzini F; Crugnola M; Bosi C; Isidori A; Auteri G; Forte D; Latagliata R; Griguolo D; Cattaneo D; Trawinska M; Bartoletti D; Krampera M; Semenzato G; Lemoli RM; Cuneo A; Di Raimondo F; Vianelli N; Cavo M; Palumbo GA
    Hematol Oncol; 2020 Aug; 38(3):372-380. PubMed ID: 32271957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myelofibrosis: an update on drug therapy in 2016.
    Bose P; Verstovsek S
    Expert Opin Pharmacother; 2016 Dec; 17(18):2375-2389. PubMed ID: 27774820
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fedratinib, a newly approved treatment for patients with myeloproliferative neoplasm-associated myelofibrosis.
    Talpaz M; Kiladjian JJ
    Leukemia; 2021 Jan; 35(1):1-17. PubMed ID: 32647323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis.
    Palandri F; Breccia M; Bonifacio M; Polverelli N; Elli EM; Benevolo G; Tiribelli M; Abruzzese E; Iurlo A; Heidel FH; Bergamaschi M; Tieghi A; Crugnola M; Cavazzini F; Binotto G; Isidori A; Sgherza N; Bosi C; Martino B; Latagliata R; Auteri G; Scaffidi L; Griguolo D; Trawinska M; Cattaneo D; Catani L; Krampera M; Lemoli RM; Cuneo A; Semenzato G; FoĆ  R; Di Raimondo F; Bartoletti D; Cavo M; Palumbo GA; Vianelli N
    Cancer; 2020 Mar; 126(6):1243-1252. PubMed ID: 31860137
    [TBL] [Abstract][Full Text] [Related]  

  • 7. State-of-the-Art Review on Myelofibrosis Therapies.
    Wang F; Qiu T; Wang H; Yang Q
    Clin Lymphoma Myeloma Leuk; 2022 May; 22(5):e350-e362. PubMed ID: 34903489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter phase 2 study of combination therapy with ruxolitinib and danazol in patients with myelofibrosis.
    Gowin K; Kosiorek H; Dueck A; Mascarenhas J; Hoffman R; Reeder C; Camoriano J; Tibes R; Gano K; Palmer J; Mesa R
    Leuk Res; 2017 Sep; 60():31-35. PubMed ID: 28646676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accelerated Phase of Myeloproliferative Neoplasms.
    Shahin OA; Chifotides HT; Bose P; Masarova L; Verstovsek S
    Acta Haematol; 2021; 144(5):484-499. PubMed ID: 33882481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The new landscape of therapy for myelofibrosis.
    Gowin K; Emanuel R; Geyer H; Mesa RA
    Curr Hematol Malig Rep; 2013 Dec; 8(4):325-32. PubMed ID: 24101258
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
    Couban S; Benevolo G; Donnellan W; Cultrera J; Koschmieder S; Verstovsek S; Hooper G; Hertig C; Tandon M; Dimier N; Malhi V; Passamonti F
    J Hematol Oncol; 2018 Sep; 11(1):122. PubMed ID: 30249277
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ruxolitinib: long-term management of patients with myelofibrosis and future directions in the treatment of myeloproliferative neoplasms.
    Yacoub A; Odenike O; Verstovsek S
    Curr Hematol Malig Rep; 2014 Dec; 9(4):350-9. PubMed ID: 25145552
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming treatment challenges in myelofibrosis and polycythemia vera: the role of ruxolitinib.
    Bryan JC; Verstovsek S
    Cancer Chemother Pharmacol; 2016 Jun; 77(6):1125-42. PubMed ID: 27017614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patterns of Ruxolitinib Therapy Failure and Its Management in Myelofibrosis: Perspectives of the Canadian Myeloproliferative Neoplasm Group.
    Gupta V; Cerquozzi S; Foltz L; Hillis C; Devlin R; Elsawy M; Grewal K; Hamm C; McNamara C; Sirhan S; Leber B
    JCO Oncol Pract; 2020 Jul; 16(7):351-359. PubMed ID: 32134707
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 1/2 Study of the Pan-PIM Kinase Inhibitor INCB053914 Alone or in Combination With Standard-of-Care Agents in Patients With Advanced Hematologic Malignancies.
    Patel MR; Donnellan W; Byrne M; Asch AS; Zeidan AM; Baer MR; Fathi AT; Kuykendall AT; Zheng F; Walker C; Cheng L; Marando C; Savona MR
    Clin Lymphoma Myeloma Leuk; 2023 Sep; 23(9):674-686. PubMed ID: 37290996
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of ruxolitinib for myelofibrosis.
    Santos FP; Verstovsek S
    Expert Opin Pharmacother; 2014 Jul; 15(10):1465-73. PubMed ID: 24856675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of ruxolitinib in the management of myelofibrosis: A single institution experience in Taiwan.
    Chen YY; Huang CE; Lee KD; Chen CC
    Hematology; 2016 Jan; 21(1):3-9. PubMed ID: 26214121
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ruxolitinib Rechallenge Can Improve Constitutional Symptoms and Splenomegaly in Patients With Myelofibrosis: A Case Series.
    Gerds A; Su D; Martynova A; Pannell B; Mukherjee S; O'Neill C; Sekeres M; O'Connell C
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e463-e468. PubMed ID: 30115545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ruxolitinib for myelofibrosis--an update of its clinical effects.
    Kantarjian HM; Silver RT; Komrokji RS; Mesa RA; Tacke R; Harrison CN
    Clin Lymphoma Myeloma Leuk; 2013 Dec; 13(6):638-45. PubMed ID: 24238036
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimizing the management of patients with myelofibrosis.
    Manea PJ
    Clin J Oncol Nurs; 2014 Jun; 18(3):330-7. PubMed ID: 24867113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.